X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (238) 238
Publication (53) 53
Book Review (16) 16
Conference Proceeding (10) 10
Patent (6) 6
Book / eBook (4) 4
Dissertation (3) 3
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (153) 153
humans (150) 150
female (119) 119
adult (111) 111
oncology (111) 111
middle aged (104) 104
male (90) 90
aged (69) 69
antineoplastic combined chemotherapy protocols - therapeutic use (59) 59
brain neoplasms - drug therapy (49) 49
malignant glioma (42) 42
chemotherapy (41) 41
treatment outcome (40) 40
bevacizumab (38) 38
cancer (37) 37
clinical neurology (36) 36
antineoplastic combined chemotherapy protocols - adverse effects (33) 33
combined modality therapy (32) 32
glioblastoma - drug therapy (31) 31
abridged index medicus (30) 30
temozolomide (30) 30
neoplasm recurrence, local - drug therapy (29) 29
article (28) 28
glioblastoma (28) 28
glioblastoma multiforme (28) 28
care and treatment (27) 27
dacarbazine - analogs & derivatives (27) 27
glioma - drug therapy (27) 27
therapy (26) 26
antineoplastic combined chemotherapy protocols - administration & dosage (25) 25
brain neoplasms - pathology (25) 25
brain neoplasms - mortality (24) 24
breast neoplasms - drug therapy (24) 24
gliomas (24) 24
transplantation (23) 23
disease-free survival (22) 22
survival analysis (22) 22
glioma (21) 21
medicine & public health (21) 21
radiotherapy (21) 21
prognosis (20) 20
retrospective studies (20) 20
breast neoplasms - therapy (19) 19
hematology (19) 19
survival rate (19) 19
camptothecin - analogs & derivatives (18) 18
angiogenesis (17) 17
antibodies, monoclonal, humanized (17) 17
brain tumors (17) 17
cyclophosphamide - administration & dosage (17) 17
follow-up studies (17) 17
glioma - pathology (17) 17
phase-ii trial (17) 17
tumors (17) 17
vascular endothelial growth factor (17) 17
breast cancer (16) 16
camptothecin - administration & dosage (16) 16
carmustine - administration & dosage (16) 16
dacarbazine - administration & dosage (16) 16
dose-response relationship, drug (16) 16
drug administration schedule (16) 16
endothelial growth-factor (16) 16
glioblastoma - pathology (16) 16
neoplasm recurrence, local - pathology (16) 16
neurology (16) 16
survival (16) 16
toxicity (16) 16
cisplatin - administration & dosage (15) 15
clinical trials (15) 15
high-dose chemotherapy (15) 15
irinotecan (15) 15
magnetic resonance imaging (15) 15
transplantation, autologous (15) 15
young adult (15) 15
angiogenesis inhibitors - therapeutic use (14) 14
antibodies, monoclonal - therapeutic use (14) 14
glioma - mortality (14) 14
maximum tolerated dose (14) 14
prospective studies (14) 14
antineoplastic agents - therapeutic use (13) 13
bone marrow transplantation (13) 13
bone-marrow transplantation (13) 13
plus irinotecan (13) 13
progression-free survival (13) 13
adolescent (12) 12
adults (12) 12
clinical investigations (12) 12
dacarbazine - adverse effects (12) 12
dacarbazine - therapeutic use (12) 12
glioblastoma-multiforme (12) 12
neoplasm recurrence, local - mortality (12) 12
radiation-therapy (12) 12
angiogenesis inhibitors (11) 11
brain neoplasms - therapy (11) 11
cyclophosphamide (11) 11
dosage and administration (11) 11
expression (11) 11
recurrence (11) 11
research (11) 11
adjuvant chemotherapy (10) 10
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
PLoS ONE, ISSN 1932-6203, 02/2012, Volume 7, Issue 2, pp. e31046 - e31046
Background: Preclinical studies in mice have demonstrated that the prophylactic depletion of immunosuppressive regulatory T-cells (T-Regs) through targeting... 
TUMOR-INFILTRATING LYMPHOCYTES | METASTATIC MELANOMA | GROWTH-FACTOR-BETA | CANCER-PATIENTS | HUMAN CYTOMEGALOVIRUS | IN-VIVO | BIOLOGY | MONOCLONAL-ANTIBODY | PERIPHERAL-BLOOD | AUTOIMMUNE-DISEASE | SELF-TOLERANCE | CD8-Positive T-Lymphocytes - cytology | T-Lymphocytes, Regulatory - metabolism | Interleukin-2 Receptor alpha Subunit - antagonists & inhibitors | CD4-Positive T-Lymphocytes - cytology | Humans | Middle Aged | Male | Brain Neoplasms - metabolism | Pilot Projects | Interleukin-2 Receptor alpha Subunit - chemistry | Immune System | T-Lymphocytes - cytology | Antibodies, Monoclonal, Humanized - pharmacology | Lymphopenia - metabolism | Immunoglobulin G - pharmacology | Adult | Female | Glioblastoma - metabolism | Aged | Immunosuppressive Agents - pharmacology | Toxicity | Brain cancer | Interleukin | Vaccination | Glioblastoma | Effector cells | Nervous system | Lymphocytes T | Vaccines | Neurosurgery | Immunity | Epidermal growth factor | Interleukin 2 | Lymphocytes | Immunotherapy | Surgery | CD25 antigen | Foxp3 protein | Immunity (humoral) | Bioinformatics | Interleukin 2 receptors | Cytomegalovirus | Immune response | Cytokines | Melanoma | Patients | CD4 antigen | Pathology | Signaling | Immunosuppression | Chemotherapy | Depletion | Lymphopenia | Monoclonal antibodies | Temozolomide | Tumors | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 03/2015, Volume 519, Issue 7543, pp. 366 - 369
After stimulation, dendritic cells(DCs) mature andmigrate to draining lymph nodes to induce immune responses(1). As such, autologous DCs generated ex vivo have... 
MALIGNANT GLIOMA | RESPONSES | IMMUNITY | MULTIDISCIPLINARY SCIENCES | HUMAN CYTOMEGALOVIRUS | VACCINATION | PERIPHERAL-BLOOD | MELANOMA-CELLS | MIP-1-ALPHA | TUMORS | T-CELLS | Phosphoproteins - immunology | Immunotherapy - methods | Viral Matrix Proteins - genetics | Chemokine CCL3 - immunology | Dendritic Cells - immunology | Humans | Substrate Specificity | Phosphoproteins - chemistry | CD4-Positive T-Lymphocytes - immunology | Cancer Vaccines - therapeutic use | Dendritic Cells - drug effects | Female | Lymph Nodes - drug effects | Tetanus Toxoid - pharmacology | Antigens, Neoplasm - immunology | Cancer Vaccines - administration & dosage | Mice, Inbred C57BL | Tetanus Toxoid - therapeutic use | Survival Rate | Treatment Outcome | Lymph Nodes - immunology | Phosphoproteins - genetics | Lymph Nodes - cytology | Tetanus Toxoid - administration & dosage | Glioblastoma - therapy | Cancer Vaccines - immunology | Cell Movement - drug effects | Animals | Glioblastoma - immunology | Viral Matrix Proteins - chemistry | Glioblastoma - pathology | Dendritic Cells - cytology | Mice | Viral Matrix Proteins - immunology | Glioblastoma - drug therapy | CD4-Positive T-Lymphocytes - drug effects | Medical research | Dendritic cells | Physiological aspects | Medicine, Experimental | Vaccines | Research | Glioblastoma multiforme | Immunization | Lymphocytes | Medical prognosis | Clinical trials | Tetanus | Chemokines | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2004, Volume 22, Issue 1, pp. 133 - 142
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4722 - 4729
Purpose Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor... 
MALIGNANT GLIOMA | BREAST-CANCER | CELLS | RESPONSES | GENE | ONCOLOGY | RESISTANCE | EGFRVIII | EXPRESSION | CONFERS | MULTIFORME PATIENTS | Immunohistochemistry | Predictive Value of Tests | Prognosis | Prospective Studies | Dacarbazine - therapeutic use | United States | Humans | Middle Aged | DNA Repair Enzymes - genetics | Gene Expression Regulation, Neoplastic | Male | Glioblastoma - radiotherapy | Brain Neoplasms - surgery | Cancer Vaccines - therapeutic use | DNA Methylation | Brain Neoplasms - immunology | Time Factors | Tumor Suppressor Proteins - genetics | Dacarbazine - analogs & derivatives | Adult | Female | Brain Neoplasms - mortality | Chemotherapy, Adjuvant | Brain Neoplasms - radiotherapy | Radiotherapy, Adjuvant | Injections, Intradermal | Receptor, Epidermal Growth Factor - immunology | Drug Administration Schedule | Enzyme-Linked Immunosorbent Assay | Glioblastoma - diagnosis | Brain Neoplasms - diagnosis | Brain Neoplasms - drug therapy | Glioblastoma - surgery | Antineoplastic Agents, Alkylating - therapeutic use | Cancer Vaccines - immunology | Disease-Free Survival | Magnetic Resonance Imaging | DNA Modification Methylases - genetics | Sample Size | Glioblastoma - immunology | Aged | Mutation | Glioblastoma - drug therapy | Glioblastoma - mortality | Index Medicus | temozolomide | glioblastoma multiforme | Epidermal growth factor receptors | Hypersensitivity (delayed) | Toxicity | Vaccination | Glioblastoma | Antibodies | Clinical trials | Vaccines | Survival | Immunogenicity | Point mutation | minimal residual disease | Tumors | Original Reports | Neur7 | Neur8 | Neur1
Journal Article
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 3/2012, Volume 107, Issue 1, pp. 155 - 164
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 1/2010, Volume 96, Issue 2, pp. 219 - 230
Journal Article
Journal of Neuro-Oncology, ISSN 0167-594X, 8/2012, Volume 109, Issue 1, pp. 63 - 70
Journal Article